LKFT
LKFT clinical trials: Lakefront Biotherapeutics NV
Every trial on ClinicalTrials.gov where Lakefront Biotherapeutics NV is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 134
- Trials linked
- 113
- As lead sponsor
- 21
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LKFT on the catalyst calendar · LKFT registry changes
- Primary completion Jul 2039Sponsor estimatePhase 3NCT06652633Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesLakefront Biotherapeutics NV · Hematological MalignanciesRecruitingLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2026ActualPhase 1/Phase 2NCT06561425A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaLakefront Biotherapeutics NV · Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2025ActualPhase 2NCT05856448A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusLakefront Biotherapeutics NV · Systemic Lupus ErythematosusCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2025ActualPhase 2NCT05695950A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisLakefront Biotherapeutics NV · DermatomyositisCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2020ActualPhase 2NCT03201445Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseLakefront Biotherapeutics NV · Inflammatory Bowel DiseaseTerminatedLKFTLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 8, 2021ActualPhase 1NCT04856358A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult SubjectsLakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 5, 2021ActualPhase 1NCT04106297A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970Lakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2020ActualPhase 1NCT04097938A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667Lakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2022ActualPhase 1NCT05272683Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsLakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2022ActualPhase 1NCT04971746Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsLakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2021ActualPhase 1NCT04720183Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy SubjectsLakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2023ActualPhase 3NCT05479058A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionLakefront Biotherapeutics NV · Ulcerative ColitisTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2023ActualPhase 3NCT02914600Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseLakefront Biotherapeutics NV · Crohn's DiseaseTerminatedLKFTLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 2NCT02065700Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsLakefront Biotherapeutics NV · Rheumatoid ArthritisCompletedLKFTLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2020ActualPhase 2NCT03926195Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis...Lakefront Biotherapeutics NV · Rheumatoid ArthritisCompletedLKFTLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 2NCT04578548A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Lakefront Biotherapeutics NV · Autosomal Dominant Polycystic Kidney DiseaseTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2010ActualPhase 1NCT01130818First-in-Human Single Ascending Dose of GLPG0492Lakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2023ActualPhase 1NCT06043739Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsLakefront Biotherapeutics NV · BioavailabilityCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2022ActualPhase 3NCT02914561Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseLakefront Biotherapeutics NV · Crohn's DiseaseCompletedLKFTLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2021ActualPhase 2NCT04700280A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)Lakefront Biotherapeutics NV · Primary Sjögren SyndromeTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2021ActualPhase 3NCT03733444A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together...Lakefront Biotherapeutics NV · Idiopathic Pulmonary FibrosisTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2021ActualPhase 3NCT03711162A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together...Lakefront Biotherapeutics NV · Idiopathic Pulmonary FibrosisTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 3, 2022ActualPhase 1NCT05335447Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667Lakefront Biotherapeutics NV · HealthyCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2021ActualPhase 2NCT04577794A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisLakefront Biotherapeutics NV · Ulcerative ColitisCompletedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2021ActualPhase 2NCT03320876An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.Lakefront Biotherapeutics NV · Psoriatic ArthritisTerminatedLKFTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 109 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner